The multicenter INFINITY registry investigates biomarker-driven treatment and management of patients with advanced malignancies not eligible for standard therapy options within routine clinical care in Germany. PD-(L)1 antibodies are frequently used in different tumor types and several biomarkers have been proposed to identify patients most likely to benefit. However, there is still a great need to further understand mechanisms of resistance to these immunotherapies. This research project was designed to analyze the genomic tumor profile and immune cell infiltration of patients with clinical benefit from PD-(L)1 antibody treatment compared to those without.
We identified all patients who received PD-(L)1 antibodies (monotherapy or in combination) from the clinical database. We used a case-control design (clinical benefit versus no-clinical benefit) based on predefined criteria: clinical benefit was defined as treatment duration >182 days and no clinical benefit was defined as treatment duration 22-63 days. 24 tissue samples were retrieved from the INFINITY biobank, 12 samples each from patients with and without clinical benefit. Next generation sequencing was performed at a central Pathology Institute (University Hospital Basel) using the Oncomine Comprehensive Assay Plus panel (Thermo Fisher). If sufficient material was available, additional analyses by Cytometry by time of flight (CyTOF) were performed (University of Basel, Dept. of Biomedicine).
Patient and disease characteristics including clinical outcome data, as well as in depth data on genomic profiling and immune cell infiltration comparing patients with vs without clinical benefit will be presented.
The biobank research project of the INFINITY registry aims to contribute to further understand mechanisms of resistance to PD-(L)1 blockade.
iOMEDICO AG.
Thermo Fisher Scientific.
P. Jermann: Financial Interests, Personal and Institutional, Invited Speaker: Thermo Fisher Scientific; Non-Financial Interests, Institutional, Research Grant, Reagent sponsoring: Thermo Fisher Scientific. H. Läubli: Non-Financial Interests, Personal and Institutional, Invited Speaker, and research support: Bristol Myers Squibb; Non-Financial Interests, Institutional, Invited Speaker: Merck Sharp & Dohme, Roche; Non-Financial Interests, Institutional, Invited Speaker, and research support: Novartis; Financial Interests, Personal, Advisory Board: GlycoEra AG, InterVenn; Financial Interests, Personal and Institutional, Advisory Board: Palleon Pharmaceutical; Non-Financial Interests, Institutional, Writing Engagements: Alector, Novocure; Financial Interests, Personal, Ownership Interest: Singenavir; Financial Interests, Personal and Institutional, Royalties: Memo Therapeutics. B. Kasenda: Financial Interests, Personal, Advisory Board: Astellas, Roche. N.W. Marschner: Financial Interests, Personal, Leadership Role: iOMEDICO; Financial Interests, Personal and Institutional, Advisory Role: MSD, Roche, Servier, Ipsen, Eisai, GSK, Beigene, AstraZeneca, Lilly, Pfizer, Novartis, Pierre Fabre, Seagen; Financial Interests, Personal, Other, Honoraria: MSD, Roche, Servier, Ipsen, Eisai, GSK, Beigene, AstraZeneca, Lilly, Pfizer, Novartis, Pierre Fabre, Seagen; Financial Interests, Institutional, Funding: MSD, Roche, Servier, Ipsen, Eisai, GSK, Beigene, AstraZeneca, Lilly, Pfizer, Novartis, Pierre Fabre, Seagen, Johnson & Johnson, Oncopeptides. All other authors have declared no conflicts of interest.